These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

443 related items for PubMed ID: 21739267

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Influence of itraconazole co-administration and CYP2D6 genotype on the pharmacokinetics of the new antipsychotic ARIPIPRAZOLE.
    Kubo M, Koue T, Inaba A, Takeda H, Maune H, Fukuda T, Azuma J.
    Drug Metab Pharmacokinet; 2005 Feb; 20(1):55-64. PubMed ID: 15770075
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Effects of genetic polymorphisms of CYP2D6, CYP3A5, and ABCB1 on the steady-state plasma concentrations of aripiprazole and its active metabolite, dehydroaripiprazole, in Japanese patients with schizophrenia.
    Suzuki T, Mihara K, Nakamura A, Kagawa S, Nagai G, Nemoto K, Kondo T.
    Ther Drug Monit; 2014 Oct; 36(5):651-5. PubMed ID: 24682161
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Venlafaxine: in vitro inhibition of CYP2D6 dependent imipramine and desipramine metabolism; comparative studies with selected SSRIs, and effects on human hepatic CYP3A4, CYP2C9 and CYP1A2.
    Ball SE, Ahern D, Scatina J, Kao J.
    Br J Clin Pharmacol; 1997 Jun; 43(6):619-26. PubMed ID: 9205822
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Reboxetine and cytochrome P450--comparison with paroxetine treatment in humans.
    Kuhn UD, Kirsch M, Merkel U, Eberhardt AM, Wenda B, Maurer I, Härtter S, Hiemke C, Volz HP, Balogh A.
    Int J Clin Pharmacol Ther; 2007 Jan; 45(1):36-46. PubMed ID: 17256449
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Antidepressant drug interactions and the cytochrome P450 system. The role of cytochrome P450 2D6.
    Ereshefsky L, Riesenman C, Lam YW.
    Clin Pharmacokinet; 1995 Jan; 29 Suppl 1():10-8; discussion 18-9. PubMed ID: 8846618
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Inhibition of alprazolam and desipramine hydroxylation in vitro by paroxetine and fluvoxamine: comparison with other selective serotonin reuptake inhibitor antidepressants.
    von Moltke LL, Greenblatt DJ, Court MH, Duan SX, Harmatz JS, Shader RI.
    J Clin Psychopharmacol; 1995 Apr; 15(2):125-31. PubMed ID: 7782485
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 23.